Journal
EXPERT REVIEW OF VACCINES
Volume 14, Issue 11, Pages 1459-1470Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2015.1081817
Keywords
conserved region vaccine; CovR/S; GAS pharyngitis; group A streptococcus; J8-DT; J8-DT+rSpyCEP; M-protein-based vaccines; polyvalent vaccine; skin infection; vaccine
Categories
Funding
- National Heart Foundation of Australia
- National Institutes of Health, USA [U01AI60579-01]
- National Health and Medical Research Council (Australia)
Ask authors/readers for more resources
Group A streptococcal (Streptococcus pyogenes) diseases remain a major public health problem in developing countries as well as in the indigenous populations of developed countries. In view of the large number of Group A streptococcal infections and the potential for sequelae such as rheumatic heart disease, control strategies including the development of an anti-streptococcal vaccine that is able to prevent infection and colonization is important. In this article, we discuss the epidemiology and strain variability of Group A streptococcus and how this is rendering vaccine development more challenging. We discuss vaccine strategies with a focus on the conserved region of the M protein and present a viewpoint for the impediments and the way forward.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available